Table 1.
Concentrations of prostate specific antigen (PSA) in men with prostate cancer metastasis (cases), controls, and men not selected as controls in participants from Malmö cohort
| Age (years) at screening | Prostate cancer metastasis | Selected controls | Not selected as controls | |
|---|---|---|---|---|
| With measured PSA* | With imputed PSA† | |||
| 37.5-42.5 at baseline | ||||
| No of participants | 18 | 54 | 710 | 3197 |
| Median (IQR) total PSA (µg/L) | 0.63 (0.49-1.42) | 0.62 (0.48-0.97) | 0.63 (0.43-0.94) | 0.61 (0.41-0.89) |
| 45-49 at baseline | ||||
| No of participants | 198 | 514 | 3190 | 6455 |
| Median (IQR) total PSA (µg/L) | 1.11 (0.62-2.41) | 0.60 (0.41-0.94) | 0.68 (0.43-1.04) | 0.68 (0.44-1.07) |
| 51-55 at second screen | ||||
| No of participants | 93 | 3970 | 0 | 0 |
| Median (IQR) total PSA (µg/L) | 1.67 (0.97-5.29) | 0.84 (0.52-1.36) | NA‡ | NA‡ |
IQR=interquartile range.
*PSA concentrations measured as part of another study.
†PSA concentrations for men without prostate cancer not selected as controls imputed to calculate population based estimates of risk.
‡PSA measured in all men.